DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Should You Buy?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $11.76, but opened at $12.20. DBV Technologies shares last traded at $11.99, with a volume of 29,690 shares.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Citizens Jmp increased their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Finally, Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Trading Up 1.9%

The stock has a market capitalization of $753.68 million, a PE ratio of -3.43 and a beta of -0.95. The firm’s 50-day moving average price is $14.11 and its 200-day moving average price is $17.41.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in shares of DBV Technologies in the fourth quarter worth approximately $32,000. Royal Bank of Canada lifted its stake in DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after acquiring an additional 2,928 shares during the period. Personal CFO Solutions LLC purchased a new stake in shares of DBV Technologies in the 1st quarter worth approximately $264,000. Cetera Investment Advisers boosted its position in DBV Technologies by 93.4% during the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after acquiring an additional 12,243 shares in the last quarter. Finally, AdvisorShares Investments LLC bought a new stake in DBV Technologies during the first quarter valued at about $1,052,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.